Amgen (AMGN) closed at $273.68 in the latest trading session, marking a -1.3% move from the prior day. This change was narrower than the S&P 500's 2.36% loss on the day. Meanwhile, the Dow lost 2. ...

Amgen made considerable strides in its oncology portfolio, as evidenced by the successful interim results for its DeLLphi-304 trial assessing IMDELLTRA for small cell lung cancer. These product ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Those phase 2 results represented a “watershed moment” for Amgen’s oncology team, chief medical officer Paul Burton, M.D., told Fierce Biotech in 2023. “This represents about a tripling of ...

Etanercept is a biologic medicine used to treat various inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Amgen, known for its focus on human therapeutics, has maintained a strong presence in the biotech industry. The company's product portfolio spans various therapeutic areas, including oncology ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.